

## Issues Related to the Use of Fish Models in Toxicologic Pathology: Session Introduction

J. MCHUGH LAW

*College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina 27606*

### ABSTRACT

Ready or not, fish models are “here to stay.” No longer are fish confined to a few specialized laboratories, nor are they exclusively the purview of zoologists or environmental toxicologists. In fact, the institution that does not house at least 1 fish facility is probably not at the forefront of cutting edge research. In toxicologic pathology, fish models are increasingly being used to provide high animal numbers at relatively low cost in carcinogenicity testing and developmental research, and to provide mechanistic information on fundamental cellular processes. In this session, we attempt to provide some perspective for the pathologist that is faced with planning or performing experiments or testing protocols using fish models, or with reading or interpreting fish studies. First, we cover how to approach fish studies from the contract laboratory standpoint, including sectioning, quality control, and GLP considerations. Then, we discuss specifics on the use of the rainbow trout, zebrafish, and Japanese medaka models. The rainbow trout has a rich history in carcinogenicity and mechanistic cancer research. Similarly, the 2 workhorses in the small fish category, zebrafish and medaka, have found their way into many laboratories doing developmental biology and genomics research as well as carcinogenicity testing. Some fascinating genetically altered fish models have been developed with both of these species. This manuscript provides a session overview of the use of small fish models in toxicologic pathology, along with some historical perspective on how these models have played a role in the current state of the science.

**Keywords.** Carcinogenicity testing; fish models; Japanese medaka; rainbow trout; zebrafish.

### INTRODUCTION

The new century finds us more than ever before in an age of rapid discovery, development, and marketing of pharmaceuticals and other chemicals that affect humans and, ultimately, all other biological systems. Hence, the need for rapid safety assessment of these compounds as well as for mechanistic developments in basic research is greater than ever. Despite calls for reducing the numbers of animals used in these efforts, ever increasing regulatory requirements and awareness of product liability demand more precision in safety testing and necessitate the use of a greater variety of test protocols in *whole* animals. In environmental impact studies, the enhanced resolution afforded by technological advancements in analytical instrumentation in turn demands the assessment of lower and lower (ie, more realistic or “environmentally relevant”) dose levels, thus requiring larger and larger numbers of test animals (higher “*n*”).

At the same time, societal pressures against animal testing have squeezed toxicologists and risk assessors from the other direction. Short-term, *in vitro* assays have been useful in mass screening of potentially toxic compounds. Although many of these assays are rapid and economical, their validity has been limited somewhat by false positives and false negatives, and by an inherent inability to determine target organ-specific effects such as carcinogenicity or promoting activity (20). In addition, the total milieu including cell-cell and cell-matrix interactions is not included in such assessments. Because whole animal testing remains the benchmark for safety assessment and even basic research, the use of

“alternative” animal models in toxicity and carcinogenicity testing has received considerable attention (40). In 1993, the US Congress instructed the National Institutes of Health to investigate the use of alternative animal models. Specifically, this called for *replacing* animals with *in vitro* tests, chemical reactions, and computer models; *reducing* the numbers of animals used; and *refining* current methods, emphasizing relief of pain, maximizing information obtained from each animal, and utilizing animals lower on the phylogenetic tree (40). In the year 2000, the National Toxicology Program Interagency Coordinating Committee on the Validation of Alternative Methods was established to assist in these efforts. Transgenic mouse models, such as the Tg.AC (zeta globin promoted v-Ha-ras) transgenic mouse (48), will answer some specific questions that require using whole animals, but these specialized models are costly and often difficult to obtain in large numbers needed for bioassays.

### FISH MODELS IN TOXICOLOGIC PATHOLOGY: HISTORICAL PERSPECTIVE

Perhaps because of their fecundity, small size, and economical maintenance and use, fish models are becoming well established in many laboratories. In fact, the facility that does not house at least 1 colony of zebrafish, medaka, or other fish species is probably not at the forefront of biomedical research (46). A number of recent reviews have pointed out the advantages of fish models for laboratory-based testing (1, 6, 21, 26, 38, 55). Small fish models have been shown to be sensitive to a variety of known carcinogens and have a short time to tumorigenesis, yet have an exceedingly low spontaneous tumor rate in potential target organs (16, 19).

Although it is widely recognized that aquatic ecosystems serve as the final sink for many chemicals, and that water serves as the ultimate vehicle for exposure to many toxic agents, relatively few methods exist to precisely and

Address correspondence to: J. M. Law, NCSU College of Veterinary Medicine, Laboratory for Toxicologic and Molecular Pathology, 617 Hutton Street, Raleigh, North Carolina 27606. Fax: (919) 515-4237; e-mail: Mac\_Law@ncsu.edu

practically assess health risks from exposure to pollutants in the aquatic environment (55). In fact, it was historical observations of tumors in wild fishes that prompted the development of carcinogenicity testing utilizing small fish species in the laboratory. Harshbarger and Clark (14) documented 41 geographic regions in North America in which clusters, or epizootics, of cancer in wild fishes have occurred. The occurrence of neoplasms involving epithelial tissues such as the liver, pancreas, gastrointestinal tract, and some epidermal neoplasms appear strongly correlated with environmental contamination, that is, exposure to chemical carcinogens. Recent reviews provide more on these epizootics (5, 8, 9, 14, 15, 34). However, several reports of tumors in wild fish have been pivotal and deserve special mention.

English sole from contaminated areas of the Puget Sound, Washington, had high prevalences of liver lesions that ranged from megalocytosis to neoplasms (37). Several detailed studies (eg, 28–32) established statistically significant associations between the presence of polycyclic aromatic hydrocarbons (PAH) in the sediments and the prevalence of liver neoplasia. Malins et al (33) identified a novel DNA adduct, 2,6-diamino-4-hydroxy-5-formamidopyrimidine, in neoplastic livers of English sole from carcinogen-impacted areas of the Puget Sound.

On the East Coast, epizootic hepatic neoplasia in winter flounder from Boston Harbor, Massachusetts, has been reported (35, 36). As in the case of the Puget Sound sole but not as firmly established, the hepatic lesions in the winter flounder were highly correlated with anthropogenic chemical contamination.

Although many incidences of cancer epizootics have occurred in fresh water fishes (5), none have been as well studied as the epizootics in the marine species the English sole and winter flounder. Epizootics of neoplasia in fish populations of brown bullhead catfish (*Ictalurus nebulosus*) and Atlantic tomcod (*Microgadus tomcod*) also should be noted. Sediments rich in PAH have generally been considered the principal causes of skin and liver neoplasia in brown bullheads in the contaminated Black River (Ohio), a tributary of Lake Erie (2–4). In laboratory tests, medaka exposed to extracts and fractions of PAH-contaminated sediments from tributaries of the Great Lakes, including the Black River, developed liver neoplasia (11). Similarly, epizootics of hepatic neoplasia have been reported from Atlantic tomcod from the Hudson River (7, 41). Those liver neoplasms have been associated with elevated tissue levels of polychlorinated biphenyls (PCBs) (22).

White suckers from industrially polluted areas of Lake Ontario exhibited increased prevalences of hepatic and skin neoplasia (17, 42). As in other epizootics, the neoplasms have been associated with PAH contamination. Stalker et al (43) showed that the progression of hepatocellular and bile duct neoplasms in the white sucker is accompanied by a loss of immunoreactive glutathione *S*-transferases that usually catalyze a major detoxification pathway.

Only a small number of reported cancer epizootics have dealt with small fish species. Vogelbein and colleagues reported high prevalences of liver neoplasms in mummichog (*Fundulus heteroclitus*) from a creosote-contaminated site in the Elizabeth River, Virginia (53). Exocrine pancreatic

neoplasms also apparently induced by contaminant exposure were later reported in these fish (12, 52).

#### THE NEED FOR MECHANISM-BASED RESEARCH

Studies involving fish in toxicology currently use these models either as surrogates for human health problems or as indicators of environmental health. Human health and environmental health are, of course, inexorably linked, so the 2 concepts should not be separated. Instead, it is critical that we provide as much mechanistic information as possible in order to further validate these alternative test methods and take every advantage of their utility for many types of studies.

Mechanistic information garnered across phyletic levels may be more accurately applied to help substantiate findings from field work. Additionally, it may unlock untold mysteries of the basic mechanisms of cellular pathology and neoplasia (recall the wealth of information garnered on apoptosis from the lowly nematode, *C. elegans*) (13).

The basic metabolic machinery in small fish species, with regard to Phase I and Phase II metabolism, is similar to that in mammals. The Phase I metabolizing enzyme system, the cytochromes P450 (CYPs), have been perhaps the best characterized in aquatic species (44, 45). At this time, it appears that in fish only members of the CYP 1A subfamily are induced by environmental toxicants, and thus would have a major impact on the activation or detoxification of carcinogens (54). Similar to mammals, compounds such as polycyclic aromatic hydrocarbons, polyhalogenated biphenyls (PCBs), and polychlorinated dioxins have been shown to induce CYP1A in fish. One important difference to note between fish and mammals, however, is in the response to phenobarbital. Whereas phenobarbital classically induces the mammalian CYP2B subfamily, fish CYP2B appears to be refractory to phenobarbital induction (23, 24). Recent studies indicate that phenobarbital can instead induce CYP1A in fish, perhaps via enhancement of Ah receptor activation (10, 39). In a recent review, Williams et al (54) point out that xenoestrogens, an important class of aquatic pollutants, may alter the response to carcinogens in fish through modulation of CYPs.

While these relationships are best characterized in the rainbow trout model, comparatively little information is available for small fish models. CYP1A was found to be deficient in preneoplastic and neoplastic lesions in mummichog (*Fundulus heteroclitus*), an estuarine small fish model that shows great promise for environmental toxicology research (51). This same group recently demonstrated tissue-specific expression of CYP1A in mummichog exposed to benzo[a]pyrene in both aqueous and dietary exposures, and developed a grading system for CYP1A staining intensity (50). Studying the metabolism of trichloroethylene, a common groundwater contaminant, Lipscomb et al (27) found that CYP1A was readily detectable in medaka liver by immunohistochemistry, whereas CYP2E1 was present at very low levels.

Other enzyme systems have shown somewhat more variable results in fish studies. Immunostaining for gamma-glutamyl transpeptidase (GGT), an important enzyme marker in rodents, detected foci of cellular alteration in medaka exposed to DEN (18). However, GGT staining showed conflicting results in rainbow trout studies (6). Glutathione-*S*-transferase, an important Phase II biotransformation

enzyme, has also shown variable results in preneoplastic and neoplastic lesions in rainbow trout (6).

These reports support the utility of tissue-specific induction patterns for biotransformation enzymes in fish carcinogenesis research. However, it is also clear that there is a need for more information on these enzyme systems, particularly in small fish models. Future bioassays using these models should include a battery of immunohistochemical stains, such as those used by Van Veld et al (1997) or Lipscomb (1998). Immunostains could provide valuable mechanistic information on carcinogen metabolism and help delineate enzyme altered foci that might otherwise be missed using routine staining methods. Furthermore, basic research is needed on induction of enzymes by various classes of carcinogens in small fish models such as the CYPs, GST, DNA repair enzymes, and the caspases involved in apoptosis. This information will be forthcoming as long as adequate funding is maintained and balanced between basic, applied, and clinical cancer research.

A virtual explosion of information is occurring in the area of molecular biology with small fish models, much of which is beyond the scope of this paper. See recent reviews for further discussion of these developments (47, 49). These molecular findings can only serve to bolster the validation of these models. Recent discoveries have supported the use of small fish models for human health risks from the environment. For example, the *ras* oncogene of fish has a high homology to human *K-ras*; in goldfish, this homology is approximately 96% (49). Point mutations in *Ki-ras* occurred in a high proportion of rainbow trout liver tumors induced by aflatoxin B<sub>1</sub>, dimethylbenzanthracene (DMBA), methyl-*N*=-nitro-*N*-nitrosoguanidine (MNNG), and DEN. The *p53* tumor suppressor gene is another important example of molecular markers. The *p53* gene has recently been cloned and sequenced in medaka, but specific mutations have yet to be demonstrated (25). However, we have seen overexpression of the *p53* protein product in liver neoplasms in several fish bioassays (unpublished work). Stabilization of a nonfunctional form of *p53* protein is thought to account for the increased expression of *p53* in tumors, suggesting a failure of this important gatekeeper of the cell cycle.

#### SESSION OVERVIEW

In this session, we attempt to provide some perspective for the pathologist that is faced with planning or performing experiments or testing protocols using fish models, or with reading or interpreting fish studies. First, Jeff Wolf of Experimental Pathology Laboratories, Herndon, VA, discusses how to approach fish studies from the contract laboratory standpoint, including special sectioning considerations, quality control, and Good Laboratory Practices (GLP) considerations. Although universal GLP standards have yet to be officially established between laboratories that conduct fish studies, recent contract work conducted "in the spirit of GLP," including quality assurance and peer review, has gained rapid acceptance and helped in moving toward interlaboratory standardization.

Next, David Williams of Oregon State University, Corvallis, Oregon, discusses specifics on the use of the rainbow trout model. Williams reviews some of the fascinating work with rainbow trout carcinogenicity testing done pre-

dominantly at Oregon State University, including testing of dietary carcinogens and those with anticarcinogenic properties. Historically, this fish model provided some critical breakthroughs in the links between dietary aflatoxin exposure and liver cancer. Jan Spitzbergen, also of Oregon State in Corvallis, next provides an overview of the multitude of scientific accomplishments afforded by the zebrafish model, particularly in the molecular mechanisms of development. Spitzbergen also reviews the current state of toxicity and carcinogenicity testing with this model, and rightly articulates the need for training of veterinary pathologists that can help make sense of the explosion of transgenic animal models, including transgenic fish models. Last, William Hawkins, Institute of Marine Sciences, Ocean Springs, Mississippi, reviews some recent studies using the Japanese medaka. The medaka has emerged as the preeminent model for large scale carcinogenicity testing, and is helping to define the dose-response curve for genotoxic carcinogens at relatively low and perhaps more environmentally realistic exposure concentrations.

#### REFERENCES

1. Bailey GS, Williams DE, Hendricks JD (1996). Fish models for environmental carcinogenesis: The rainbow trout. *Environ Health Perspec* 104: 5-21.
2. Baumann PC (1989). PAH, metabolites, and neoplasia in feral fish populations. In: *Metabolism of Polycyclic Aromatic Hydrocarbons in the Aquatic Environment*, Varanasi U (ed). CRC Press, Boca Raton, Florida, pp. 269-290.
3. Baumann PC, Harshbarger JC, Hartman KJ (1990). Relationship between liver tumors and age in brown bullhead populations from two Lake Erie tributaries. *Sci Total Environ* 94: 71-87.
4. Baumann PC, Smith WD, Parland WK (1987). Tumor frequencies and contaminant concentrations in brown bullheads from an industrialized river and a recreational lake. *Trans Amer Fish Soc* 116: 79-86.
5. Black JJ, Baumann PC (1991). Carcinogens and cancers in freshwater fishes. *Environ Health Perspec* 90: 27-33.
6. Bunton TE (1996). Experimental chemical carcinogenesis in fish. *Toxicol Pathol* 24: 603-618.
7. Cormier SM, Racine RN, Smith CE, Dey WP, Peck TH (1989). Hepatocellular carcinoma and fatty infiltration in the Atlantic tomcod, *Microgadus tomcod* (Walbaum). *J Fish Dis* 12: 105-116.
8. Couch JA, Harshbarger JC (1985). Effects of carcinogenic agents on aquatic animals: An environmental and experimental overview. *Environ Carcinogen Revs* 3: 63-105.
9. Dawe CJ, Harshbarger JC, Kondo S (eds) (1981). *Phyletic Approaches to Cancer*. Japan Scientific Societies Press, Tokyo.
10. Elskus AA, Stegeman JJ (1989). Further consideration of phenobarbital effects on cytochrome P-450 activity in killifish, *Fundulus heteroclitus*. *Comp Biochem Physiol* 92C: 223-230.
11. Fabacher DL, Besser JM, Schmitt CJ, Harshbarger JC, Peterman PH, Lebo JA (1991). Contaminated sediments from tributaries of the Great Lakes: Chemical characterization and carcinogenic effects in medaka (*Oryzias latipes*). *Arch Environ Contam Toxicol* 20: 17-34.
12. Fournie JW, Vogelbein WK (1994). Exocrine pancreatic neoplasms in the mummichog (*Fundulus heteroclitus*) from a creosote-contaminated site. *Toxicol Pathol* 22: 237-247.
13. Fraser AG (1999). Programmed cell death in *C. elegans*. *Cancer Metastasis Rev* 18: 285-294.
14. Harshbarger JC, Clark JB (1990). Epizootiology of neoplasms in bony fish of North America. *Sci Total Environ* 94: 1-32.
15. Harshbarger JC, Spero PM, Wolcott NM (1993). Neoplasms in wild fish from the marine ecosystem emphasizing environmental interactions. In: *Pathobiology of Marine and Estuarine Organisms*, Couch JA, Fournie JW (eds). CRC Press, Boca Raton, Florida, pp 157-176.



16. Hawkins WE, Overstreet RM, Walker WW (1988). Carcinogenicity tests with small fish species. *Aquatic Toxicol* 11: 113–128.
17. Hayes MA, Smith IR, Rushmore TH, Crane TL, Thorm C, Kocal TE, Ferguson HW (1990). Pathogenesis of skin and liver neoplasms from industrially polluted areas in Lake Ontario. *Sci Total Environ* 94: 105–123.
18. Hinton DE, Couch JA, The SJ, Courtney LA (1988). Cytological changes during progression of neoplasia in selected fish species. *Aquatic Toxicol* 11: 77–112.
19. Hoover KL (ed) (1984). *Use of Small Fish Species in Carcinogenicity Testing*, Vol. 65, National Cancer Institute, Bethesda, Maryland.
20. Ito N, Tatematsu M, Hasegawa R, Tsuda H (1989). Medium-term bioassay system for detection of carcinogens and modifiers of hepatocarcinogenesis utilizing the GST-P positive liver cell focus as an endpoint marker. *Toxicol Pathol* 17: 630–641.
21. Kazianis S, Walter RB (2002). Use of platyfishes and swordtails in biological research. *Lab Animal* 31: 46–52.
22. Klauda RV, Peck TH, Rice GK (1981). Accumulation of polychlorinated biphenyls in Atlantic tomcod (*Microgadus tomcod*) collected from the Hudson River estuary, New York. *Bull Environ Contam Toxicol* 27: 829–835.
23. Kleinow KM, Haasch ML, Williams DE, Lech JJ (1990). A comparison of hepatic P450 induction in rat and trout (*Onchorhynchus mykiss*): Delineation of the site of resistance of fish to phenobarbital-type inducers. *Comp Biochem Physiol* 96C: 259–270.
24. Kleinow KM, Melancon MJ, Lech JJ (1987). Biotransformation and induction: Implications for toxicity, bioaccumulation, and monitoring of environmental xenobiotics in fish. *Environ Health Perspec* 71: 105–119.
25. Krause M, Rhodes L, Van Beneden R (1997). Cloning of the *p53* tumor suppressor gene from the Japanese medaka (*Oryzias latipes*) and evaluation of mutational hotspots in MNNG-exposed fish. *Gene* 189: 101–106.
26. Law JM (2001). Mechanistic considerations in small fish carcinogenicity testing. *ILAR J* 42: 274–284.
27. Lipscomb J, Confer P, Miller M, Stamm S, Snawder J, Bandiera S (1998). Metabolism of trichloroethylene and chloral hydrate by the Japanese medaka (*Oryzias latipes*) in vitro. *Environ Toxicol Chem* 17: 325–332.
28. Malins DC, Krahn MM, Brown DW, Rhodes LD, Myers MS, McCain BB, Chan S-L (1985). Toxic chemicals in marine sediment and biota from Mukilteo, Washington: Relationships with hepatic neoplasms and other hepatic lesions in English sole (*Parophrys vetulus*). *J Natl Cancer Inst* 74: 487–494.
29. Malins DC, Krahn MM, Myers MS (1985). Toxic chemicals in sediments and biota from a creosote-polluted harbor: Relationships with hepatic neoplasms and other hepatic lesions in English sole (*Parophrys vetulus*). *Carcinogenesis* 6: 1463–1469.
30. Malins DC, McCain BB, Brown DW, Chan SL, Myers MS, Landahl JT, Prohaska PG, Frideman AJ, Rhodes LD, Burrows DG, Gronlund WG, Hodgins HO (1984). Chemical pollutants in sediments and diseases of bottom-dwelling fish in Puget Sound, Washington. *Environ Sci Technol* 18: 705–713.
31. Malins DC, McCain BB, Landahl JT (1988). Neoplastic and other diseases in fish in relation to toxic chemicals: An overview. *Aquatic Toxicol* 11: 43–67.
32. Malins DC, McCain BB, Myers MS (1987). Field and laboratory studies of the etiology of liver neoplasms in marine fish from Puget Sound. *Environ Health Perspec* 71: 5–16.
33. Malins DC, Ostrander GK, Haimanot R, Williams P (1990). A novel DNA lesion in neoplastic livers of feral fish: 2,6-diamino-4-hydroxy-5-formamidopyrimidine. *Carcinogenesis* 11: 1045–1047.
34. Mix MC (1986). Cancerous diseases in aquatic animals and their association with environmental pollutants: A critical review of the literature. *Mar Environ Res* 20: 1–141.
35. Murchelano RA, Wolke RE (1985). Epizootic carcinoma in winter flounder, *Pseudopleuronectes americanus*. *Science* 228: 587–589.
36. Murchelano RA, Wolke RE (1991). Neoplasms and nonneoplastic lesions in winter flounder, *Pseudopleuronectes americanus*, from Boston Harbor, Massachusetts. *Environ Health Perspec* 90: 17–26.
37. Myers MS, Landahl JT, Krahn MM, McCain BB (1991). Relationships between hepatic neoplasms and related lesions and exposure to toxic chemicals in marine fish from the U.S. West Coast. *Environ Health Perspec* 90: 7–15.
38. Powers DA (1989). Fish as model systems. *Science* 246: 352–358.
39. Sadar MD, Ash R, Sundqvist J, Olsson PE, Andersson TB (1996). Phenobarbital induction of CYP1A1 gene expression in a primary culture of rainbow trout hepatocytes. *J Biol Chem* 271: 17635–17643.
40. Salem H, Katz S (ed) (1998). *Advances in Animal Alternatives for Safety and Efficacy Testing*, Taylor & Francis, Philadelphia, PA.
41. Smith CE, Peck TH, Klauda RJ, McLaren JB (1979). Hepatomas in Atlantic tomcod *Microgadus tomcod* (Walbaum) collected in the Hudson River estuary in New York. *J Fish Dis* 2: 313–319.
42. Sonstegard RA (1977). Environmental carcinogenesis studies in fishes of the Great Lakes of North America. *Ann NY Acad Sci* 298: 261–269.
43. Stalker MJ, Kirby GM, Kocal TE, Smith IR, Hayes MA (1991). Loss of glutathione *S*-transferases in pollution-associated liver neoplasms in white suckers (*Catostomus commersoni*) from Lake Ontario. *Carcinogenesis* 12: 2221–2226.
44. Stegeman JJ, Hahn ME (1994). Biochemistry and molecular biology of monooxygenases: Current perspectives on forms, functions, and regulation of cytochrome P450 in aquatic species. In: *Aquatic Toxicology: Molecular, Biochemical, and Cellular Perspectives*, Malins DC, Ostrander GK (eds). Lewis Publishers, Boca Raton, Florida, pp 87–206.
45. Stegeman JJ, Lech JJ (1991). Cytochrome P-450 monooxygenase systems in aquatic species: Carcinogen metabolism and biomarkers for carcinogen and pollutant exposure. *Environ Health Perspec* 90: 101–109.
46. Stoskopf MK (2002). Fish are here to stay. *Lab Animal* 31: 9.
47. Talbot W, Hopkins N (2000). Zebrafish mutations and functional analysis of the vertebrate genome. *Genes Devel* 14: 755–762.
48. Tennant R, Tice R, Spalding J (1998). The transgenic Tg.AC mouse model for identification of chemical carcinogens. *Toxicol Lett* 102–103: 465–471.
49. Van Beneden RJ, Ostrander GK (1994). Expression of oncogenes and tumor suppressor genes in teleost fishes. In: *Aquatic Toxicology: Molecular, Biochemical, and Cellular Perspectives*, Malins DC, Ostrander GK (eds). Lewis Publishers, Boca Raton, Florida, pp 295–325.
50. Van Veld P, Vogelbein W, Cochran M, Goksoyr A, Stegeman J (1997). Route-specific cellular expression of cytochrome P4501A (CYP1A) in fish (*Fundulus heteroclitus*) following exposure to aqueous and dietary benzo[a]pyrene. *Toxicol Appl Pharmacol* 142: 348–359.
51. Van Veld P, Vogelbein W, Smolowitz R, Woodin B, Stegeman J (1992). Cytochrome P4501A1 in hepatic lesions of a teleost fish (*Fundulus heteroclitus*) collected from a polycyclic aromatic hydrocarbon-contaminated site. *Carcinogenesis* 13: 505–507.
52. Vogelbein WK, Fournie JW (1994). Ultrastructure of normal and neoplastic exocrine pancreas in the mummichog, *Fundulus heteroclitus*. *Toxicol Pathol* 22: 248–260.
53. Vogelbein WK, Fournie JW, Van Veld PA, Hugggett RJ (1990). Hepatic neoplasms in the mummichog *Fundulus heteroclitus* from a creosote-contaminated site. *Cancer Res* 50: 5978–5986.
54. Williams DE, Lech JJ, Buhler DR (1998). Xenobiotics and xenoestrogens in fish: Modulation of cytochrome P450 and carcinogenesis. *Mutation Res* 399: 179–192.
55. Winn RN (2001). Transgenic fish as models in environmental toxicology. *ILAR J* 42: 322–329.